Rotigotine transdermal - UCB

Drug Profile

Rotigotine transdermal - UCB

Alternative Names: Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; Rotigotine PR2.1.1; Rotigotine PR2.2.1; SPM-962

Latest Information Update: 11 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aderis Pharmaceuticals
  • Developer Abbott Laboratories; Andromaco; Otsuka Pharmaceutical; UCB
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • No development reported Fibromyalgia

Most Recent Events

  • 03 Jul 2018 Registered for Parkinson's disease (Adjunctive treatment, Late-stage disease) in China (Transdermal)
  • 02 Jul 2018 Preregistration for Parkinson's disease (Adjunctive treatment, Late-stage disease) in China (Transdermal) before July 2018
  • 02 Jul 2018 Preregistration for Parkinson's disease (Early-stage disease, Monotherapy) in China (Transdermal) before July 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top